Podcasts about Vertex Pharmaceuticals

Market volatility is starting to decrease, and markets are returning to a more normal state. The short-term picture is slowly moving into overbought territory, while both the medium- and long-term outlooks are still flashing strong buy signals.On Wednesday, the Fed and Chair Powell will announce the interest rate decision, with markets widely anticipating no change.Throughout the week, several high-profile companies will report their quarterly results, including Palantir, AMD, Vertex Pharmaceuticals, Disney, Uber, Shopify, and others.All this and more in this week's "Trading Tips With Jim."#StockMarket #MarketUpdate #TradingTips #Investing #StockAnalysis #Palantir #AMD #VertexPharmaceuticals #Disney #Uber #Shopify #EarningsSeason #FederalReserve #Powell #InterestRates #BuySignals #MarketOutlook

In this episode, Mark Longo, Henry Schwartz (Cboe) and Mike Tosaw (St. Charles Wealth Management) hosts delve into current market trends, unusual options activity, and listener questions. They discuss VIX movement, the resurgence of gold, and controversial trades ahead of the tariff announcement. New options products, such as the S&P Equal Weighted 500 Index options, are introduced, and there's an examination of activity in Vertex Pharmaceuticals, NeoGenomics, Eldorado Gold Corp, and Dynatrace. The hosts also review audience poll results on zero-day options trading and the viability of certain puts in Apple and Nvidia. 00:00 Introduction to Options Insider Radio Network 01:18 Meet the Hosts and Sponsors 03:16 Market Overview and Trading Block 05:41 Volatility and Market Trends 13:13 Gold and Precious Metals Discussion 15:43 Options Market Activity 30:55 Unusual Options Activity in Vertex Pharmaceuticals 33:48 Biotech and Option Flow Insights 34:51 NeoGenomics Inc: A Rough Year 37:21 Gold's Impressive Run 43:13 Dynatrace Inc: Tech Observability 47:01 Mail Block: Listener Questions 57:56 Around the Block: Market Watch  

In this episode, Mark Longo, Henry Schwartz (Cboe) and Mike Tosaw (St. Charles Wealth Management) hosts delve into current market trends, unusual options activity, and listener questions. They discuss VIX movement, the resurgence of gold, and controversial trades ahead of the tariff announcement. New options products, such as the S&P Equal Weighted 500 Index options, are introduced, and there's an examination of activity in Vertex Pharmaceuticals, NeoGenomics, Eldorado Gold Corp, and Dynatrace. The hosts also review audience poll results on zero-day options trading and the viability of certain puts in Apple and Nvidia. 00:00 Introduction to Options Insider Radio Network 01:18 Meet the Hosts and Sponsors 03:16 Market Overview and Trading Block 05:41 Volatility and Market Trends 13:13 Gold and Precious Metals Discussion 15:43 Options Market Activity 30:55 Unusual Options Activity in Vertex Pharmaceuticals 33:48 Biotech and Option Flow Insights 34:51 NeoGenomics Inc: A Rough Year 37:21 Gold's Impressive Run 43:13 Dynatrace Inc: Tech Observability 47:01 Mail Block: Listener Questions 57:56 Around the Block: Market Watch  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Think you're just a boss? Nah, you could be a mentor—and it might just change your team, your career, and even your bottom line. Let's unpack why, with some important stats, real stories, and takeaways you can use tomorrow. Let's take a look. First off, mentoring isn't just warm fuzzies—it's can be a game-changer for all those involved. Research says mentees get promoted five times more often than those without mentors, and retention jumps by 22%. That's from McCarthy Mentoring's 2017 study, and it's not just relevant, but growing in importance in in 2025. Imagine keeping your best people longer and seeing them climb the ladder—all because you took time to guide them. That's power! Here in Australia, COX Architecture saw this firsthand. After growing fast, their Sydney team—500 strong—used mentoring to tighten bonds and set sharper goals. Staff started to redefine and focus on their career paths, and the resulting morale? Unbeatable. Check it out on Parlour's site if you're curious. I'll include the links on the blog I've connected to this podcast. Now, let's talk diversity. Mentoring lifts everyone. Cornell University found it boosts minority leadership roles by up to 24%. In Aussie terms, look at the Australian Business and Community Network—ABCN. They went digital with Accenture in 2020, mentoring disadvantaged kids, including Indigenous communities. Result? 42% felt more confident about their future. That's not just feel-good—it's building a pipeline of diverse talent. As a manager, you could do that too! Okay, here's a stat to chew on: 71% of Fortune 500 companies run mentoring programs. It's not a trend—it's a standard. Down under, AusIMM's 2024 program hooked up over 100 mining pros. Mentors reported a 20% jump in job satisfaction—proof you don't just help others, you grow too. And get this: Cox Automotive saved over $3 million in turnover costs since 2017 with mentoring. That's cash you could keep in your budget! So, real-world wins? Plenty. Avison Young pushed women into leadership with mentoring—diversity ticked up fast. Vertex Pharmaceuticals went global, mixing reverse mentoring with peer circles—genius for multigenerational teams. And Paychex? Their high-potential women hit 94% retention. These aren't flukes; they're proof mentoring works. Locally, ABCN's online shift delivered 179 sessions in a year—regional kids got a leg up. That's mentoring breaking barriers, right here in Oz. Takeaways time! One: mentoring keeps talent and cuts costs—think millions, not pennies. Two: it's your diversity secret weapon—lift up underrepresented voices. Three: you'll grow as a leader—satisfaction and skills, sorted. How do you start? Assess your team's needs, pair people smartly, and track the wins—engagement, retention, you name it.

Fund your account in five minutes or less at https://www.public.com/CSI and get up to $10,000 when you transfer your old portfolio. Join us on Discord with Semiconductor Insider: https://ko-fi.com/chipstockinvestor/tiersIn this episode of Chip Stock Investor, Kasey discusses Vertex Pharmaceuticals which was a recent addition to the Chip Stock Investor portfolio. Vertex had two new approvals before the most recent earnings report with more to come in the coming years. Will 2025 be a breakout year for Vertex?Supercharge your analysis with AI! Get 15% of your membership with our special link here: https://finchat.io/csi/Affiliate links that are sprinkled in throughout this video. If something catches your eye and you decide to buy it, we might earn a little coffee money. Thanks for helping us (Kasey) fuel our caffeine addiction!Content in this video is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. #vertexstock #vrtx #newpainmedication #pharmastocks #healthcarestocks #semiconductors #chips #investing #stocks #finance #financeeducation #financeeducation #finance #stocks #investing #investor #financeeducation #stockmarket #chipstockinvestor #semiconductorstocks Nick and Kasey own shares of Vertex PharmaceuticalsPublic Disclosure:All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Public Investing, Inc., member FINRA & SIPC. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank. Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1890144), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. A Bond Account is a self-directed brokerage account with Public Investing, member FINRA/SIPC. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. The 6%+ yield is the average, annualized yield to worst (YTW) across all ten bonds in the Bond Account, before fees, as of 12/13/2024. A bond's yield is a function of its market price, which can fluctuate; therefore, a bond's YTW is not “locked in” until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The “locked in” YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our Fee Schedule. Bond Accounts are not recommendations of individual bonds or default allocations. The bonds in the Bond Account have not been selected based on your needs or risk profile. See Bond Account Disclosures to learn more.Alpha is an AI research tool powered by GPT-4. Alpha is experimental and may generate inaccurate responses. Output from Alpha should not be construed as investment research or recommendations, and should not serve as the basis for any investment decision. Public makes no warranties about its accuracy, completeness, quality, or timeliness of any Alpha out. Please independently evaluate and verify any such output for your own use case.*Terms and Conditions apply.

It's the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for? Also, non-mixing layers of water and hydrocarbons thousands of miles deep could explain the icy planets' strange magnetic fields.The FDA Approves A New, Non-Opioid PainkillerIn January, the Food and Drug Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex Pharmaceuticals. It's the first time in 25 years the agency has given the green light to a new painkiller. Notably, it's not an opioid and, according to the company, it's not addictive. Unlike opioids, which act directly on the brain, Journavx instead blocks nerve endings across the body that transmit pain.Host Ira Flatow is joined by Dr. Sean Mackey, a professor of anaesthesiology and pain medicine at Stanford University and chief of the Division of Stanford Pain Medicine, to discuss how the new drug works, who should take it, and what its limitations are.Might Uranus And Neptune Have Deep, Multi-Layer Oceans?We've got a pretty good idea about what's beneath the surface of our nearest planetary neighbors, like Mars. But as you get farther out into the solar system, our knowledge becomes scarce. For instance, what's inside the so-called ice giants, Neptune and Uranus?Recent research based on computer simulations of fluids hints that the planets could contain vast multi-layered oceans, as much as thousands of miles deep. A layer of water that is on top of—but doesn't mix with—a deeper layer of hydrocarbons could help explain strange magnetic fields observed during the Voyager mission.Dr. Burkhardt Militzer, a professor of earth and planetary sciences at UC Berkeley, wrote about this idea in the Proceedings of the National Academy of Sciences. He joins Host Ira Flatow to explain his theories.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Moderate—but not excessive—exercise can curb appetite; When you're older does your ability to absorb supplements decline? FDA warns against eye drop to change eye color; Are soy supplements safe for breast cancer patients? Most ditch GLP-1 drugs after one year; Some B-complex supplements don't deliver full suite of B vitamins; Novel non-addictive pain drug approved; Why mosquitoes can bite in mid-winter; Oops—surgeon removes patient's liver, mistaking it for spleen. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Pfizer announces positive results for COVID-19 vaccinePfizer has recently announced positive results from their phase 3 clinical trial for their COVID-19 vaccine. The vaccine showed over 90% effectiveness in preventing COVID-19 in participants. This is a promising development in the fight against the pandemic.## Moderna seeking emergency use authorization for COVID-19 vaccineModerna is seeking emergency use authorization from the FDA for their COVID-19 vaccine. The vaccine has shown promising results in clinical trials and could be available to the public soon. This is another step forward in the race to develop a safe and effective vaccine against COVID-19. ## AstraZeneca facing challenges with COVID-19 vaccine trialAstraZeneca has faced challenges with their COVID-19 vaccine trial, as some participants experienced adverse reactions. The company has paused the trial to investigate these reactions and ensure the safety of the vaccine. This highlights the importance of rigorous testing and monitoring in vaccine development.## Johnson & Johnson pauses COVID-19 vaccine trialJohnson & Johnson has also paused their COVID-19 vaccine trial due to an unexplained illness in a participant. The company is investigating the illness to determine if it is related to the vaccine. This pause emphasizes the need for thorough safety monitoring in clinical trials.## Roche launches rapid antigen test for COVID-19Roche has launched a rapid antigen test for COVID-19 that provides results in just 15 minutes. The test is designed for use in point-of-care settings and can help quickly identify individuals infected with the virus. This could be a valuable tool in controlling the spread of COVID-19.## Novartis acquires Vedere BioNovartis has acquired Vedere Bio, a company focused on developing gene therapies for vision loss. This acquisition expands Novartis' capabilities in gene therapy and strengthens their position in the ophthalmology market. It also demonstrates Novartis' commitment to advancing innovative treatments for patients with vision disorders.## Gilead Sciences receives FDA approval for TrodelvyGilead Sciences has received FDA approval for Trodelvy, a treatment for metastatic triple-negative breast cancer. Trodelvy has shown promising results in clinical trials and provides a new treatment option for patients with this aggressive form of breast cancer. This approval represents an important milestone in the fight against breast cancer.## Vertex Pharmaceuticals acquires Semma TherapeuticsVertex Pharmaceuticals has acquired Semma Therapeutics, a company focused on developing cell-based therapies for diabetes. This acquisition enhances Vertex's pipeline in regenerative medicine and strengthens their commitment to finding a cure for diabetes. It also highlights the growing interest in cell therapy as a treatment approach for chronic diseases.## Eli Lilly announces positive results for Alzheimer's drugEli Lilly has announced positive results from their phase 2 clinical trial for an Alzheimer's drug targeting amyloid plaques in the brain. The drug showed a significant reduction in amyloid levels compared to placebo, indicating potential disease-modifying effects. This is a hopeful development in the search for effective treatments for Alzheimer's disease.## Amgen launches biosimilar of AvastinAmgen has launched a biosimilar of Avastin, a widely used cancer drug that targets blood vessel growth in tumors. The biosimilar, known as Mvasi, offers a more affordable alternative to Avastin while maintaining similar efficacy and safety profiles. This provides patients with greater access to critical cancer treatments at lower costs.## ConclusionIn conclusion, there have been several significant developments in the Pharma and Biotech industry recently. From promising results for COVID-19 vacci

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vertex Pharmaceuticals experienced a 13% decrease in its share price following the disappointing results of its non-opioid pain therapy, suzetrigine, in a Phase II trial. Meanwhile, major players like Bayer, Bristol Myers Squibb, and Johnson & Johnson announced significant layoffs, impacting hundreds or even thousands of employees. Roche also faced setbacks as their Parkinson's drug failed to meet expectations in a mid-stage trial. Novartis made the decision to cut jobs in both Boston and Munich, while Mesoblast celebrated FDA approval for a mesenchymal stromal cell therapy for GVHD.On a more positive note, the FDA confirmed that there is no shortage of Lilly's GLP-1s and provided compounding pharmacies with a grace period before implementing new regulations to halt their production. Intelligencia AI's accurate pre-ASH predictions for high-potential biotechs demonstrated the efficacy of its predictive AI methodology. Amidst these challenges and changes, the biopharma industry is navigating evolving market dynamics and making strategic decisions to adapt to the shifting landscape.

Today's coverage kicks off with a market panel featuring Barbara Doran of BD8 Capital Partners and Phil Camporeale of J.P. Morgan Asset Management. Earnings highlights include RH, Broadcom, and Costco, with expert analysis from Bernstein's Stacy Rasgon on Broadcom and DA Davidson's Michael Baker on Costco. Globalstar CEO Paul Jacobs discusses investor day developments and reports of Apple Watch integration. Our Angelica Peebles reports on Vertex Pharmaceuticals' non-opioid pain medication and its potential market impact.

Las bolsas esperan el mensaje de Lagarde y la bajada de tipos del BCE. Pocos movimientos. Alemania con una ligera subida, Francia más pendiente de la política y España con el foco puesto en Grifols e Inditex. Aprovecharía el recorte de estos dos últimos días en Inditex para tomar posiciones: la zona de los 48/50 euros es un buen nivel de compra. Planteamos dentro de la bolsa española tb Repsol y BBVA, muy cerca de romper los 9.64 euros, resistencia importante. En nuestro Consultorio de Bolsa de hoy contamos con Samuel Plaza, Director de JFD BROKERS España. Con el analista vemos los siguientes valores: Colonial, Bayer, Inmobiliaria Colonial, Merlin Properties, Fresenius, TITAN Cement, Adidas, Marel, InPost, Farming Group, AENA, Vertex Pharmaceuticals, Palo Alto y IONQ.

In the fifth Season of the National Institute of Neurological Disorders and Stroke's Building Up the Nerve podcast, we help you strengthen your science communication skills with tools and advice to use throughout your career. We know that navigating your career can be daunting, but we're here to help—it's our job!In the sixth episode of the season, we talk about Writing Impactful Publications, focusing on how to structure and write a paper, choose a journal, and craft engaging and accessible figures.Featuring Bang Wong, MA, MS, Senior Director at Vertex Pharmaceuticals; Marina Picciotto, PhD, Professor at Yale University; and Tanya Garcia, PhD, Associate Professor at University of North Carolina, Chapel Hill.ResourcesReferenced paper by Dr. Amy Arnsten: Wang, Min, et al. "α2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex." Cell 129.2 (2007): 397-410. https://www.cell.com/fulltext/S0092-8674(07)00344-3?large_figure=true Referenced Papers by Bang Wong:Wong, B. Design of data figures. Nat Methods 7, 665 (2010). https://doi.org/10.1038/nmeth0910-665 Wong, B. Color coding. Nat Methods 7, 573 (2010). https://doi.org/10.1038/nmeth0810-573Wong, B. Points of view: Color blindness. Nat Methods 8, 441 (2011). https://doi.org/10.1038/nmeth.1618Check out more of Bang's papers: https://www.nature.com/search?author=Bang%20WongColor Contract website:Example: https://webaim.org/resources/contrastchecker/Writing Science: How to Write Papers That Get Cited and Proposals That Get Funded. By Joshua Schimel: https://global.oup.com/academic/product/writing-science-9780199760244 Experimental Design Editorials in the Journal of Neuroscience https://www.jneurosci.org/collection/experimental-design-editorialsTranscript available at http://ninds.buzzsprout.com/.

On today's episode of The Big Podcast, NBA legends reunite as we welcome basketball legend and kidney health advocate, Alonzo Mourning, to the show. Between Shaq and ‘Zo's battles on the court, their contrasting lifestyles (wait until you hear about ‘Zo's diet vs. Shaq's!), and other stories from back in the day, these two legends have plenty to laugh about. But it's not all jokes—Alonzo shares his powerful journey with APOL1-mediated kidney disease (AMKD) and his mission with Power Forward (www.PowerForwardTogether.com) to educate others about this rapidly progressive kidney disease. Tune in for an inspiring conversation and some classic Shaq-and-'Zo banter you don't want to miss!This episode is sponsored by Vertex Pharmaceuticals Incorporated. Alonzo Mourning is a paid spokesperson for Vertex Pharmaceuticals.Don't miss out on all the action this week at DraftKings! Download the DraftKings app today! Sign-up using https://dkng.co/ogs or through my promo code BIGPODZipRecruiter. The smartest way to hire. Go to this exclusive web address to try ZipRecruiter for FREE: http://ZipRecruiter.com/BIGDownload the Gametime app today or http://Gametime.co for $20 off your first order with code BIGPODBuy Liquid Death With Free Shipping on Amazon or http://liquiddeath.com/BIGPODWant to bite Shaq's head off? Get some Shaq-A-Licious at your local Walmart!Subscribe to The Big Podcast YouTube Channel to watch more episodes!Follow us on all platforms: https://linktr.ee/bigpodcast00:00 Intro02:18 Zo saved Shaq in the Finals?06:18 In memory of Dikembe Mutombo12:15 DK segment14:00 DK ad15:10 VRTX ad16:20 Lack of rivalries in current NBA19:05 Today's Big Men23:12 Gametime ad24:25 Liquid Death ad25:40 Alonzo opens up on forced retirement37:00 How Zo takes care of his health53:00 Shaq vs Heat Culture56:44 Being teammates with Shaq59:12 What current players could've handled their era?01:01:10 Zo reviews Shaq's diet and lifestyle01:05:35 Shaqalicious segment01:10:17 Vince Carter dunk01:13:09 Bench meme01:16:07 EndingGAMBLING PROBLEM? CALL 1-800-GAMBLER, (800) 327-5050 or visit gamblinghelplinema.org (MA). Call 877-8-HOPENY/text HOPENY (467369) (NY).Please Gamble Responsibly. 888-789-7777/visit ccpg.org (CT), or visit www.mdgamblinghelp.org (MD).21+ and present in most states. (18+ DC/KY/NH/WY). Void in ONT/OR/NH. Eligibility restrictions apply. On behalf of Boot Hill Casino & Resort (KS).1 per new customer. Min. $5 deposit. Min. $5 bet. Max. $150 issued as non-withdrawable Bonus Bets if your bet wins. Bonus Bets expire in 7 days (168 hours). Stake removed from payout. Terms: dkng.co/dk-offer-terms. Ends 1/5/25 at 11:59 PM ET. Sponsored by DK.MB01RGAXHH8FSSS#nba #lakers #shaq #bigpod #basketball #bigshaq #bigpodcast #alonzomorning Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Beam Therapeutics reported a patient death in a gene editing trial for sickle cell disease, overshadowing otherwise positive data. Beam-101 was found to be competitive with approved treatments, highlighting the need for less-toxic preconditioning treatments. Sana Biotechnology is planning workforce cuts to reprioritize focus on its type 1 diabetes program and extend its cash runway. Astrazeneca has received promising early data for candidates in its obesity pipeline. Vertex Pharmaceuticals exceeded its Q3 forecast and raised full-year revenue guidance. Sana Biotechnology is gearing up for potential approvals for cystic fibrosis and non-opioid therapy. The FDA delayed a decision on Merus' bispecific antibody and lawsuits were filed by the family of Henrietta Lacks seeking a share of profits from HeLa cells.The impact of the presidential election on biopharma is being closely monitored.

APAC stocks began the week mostly positive but with the gains capped ahead of this week's major risk events including the US Presidential Election.PredictIt odds shifted over the weekend in favour of a Harris election victory; NYT/Siena final polls showed the race was deadlocked in 6/7 battleground states.European equity futures are indicative of a steady cash open with the Euro Stoxx 50 future +0.1% after the cash market closed higher by 1.0% on Friday.DXY is softer vs. peers in a scaling back of the USD supportive "Trump trade"; JPY and antipodeans have been the main beneficiaries.OPEC+ agreed to delay the December oil output increase by one month, according to a Reuters source.Looking ahead, highlights include EZ Sentix Index, Manufacturing PMIs, US Employment Trends, US Durable Goods, Australian PMIs (Final), Comments from ECB's Elderson, Supply from EU & US.Earnings from Volvo Car AB, Ryanair, Kingspan, Fidelity National Information Services, NXP Semiconductors, Vertex Pharmaceuticals, Diamondback Energy, Palantir Technologies, Marriott International & Fox.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

European bourses generally trade very modestly in positive territory, alongside slight gains in US futures.PredictIt odds shifted over the weekend in favour of a Harris election victory; NYT/Siena final polls showed the race was deadlocked in 6/7 battleground states.USD is on the backfoot as a shift in polling in the US election towards Harris has seen a scaling back of "Trump trades" across the board.USTs benefit from a scaling back of the Trump trade, whilst Bunds lag; reports suggesting that China's NPC is reviewing local government debt swaps weighed on the complex.Crude benefits amid reports that OPEC+ agreed to delay the December oil output increase by one month; base metals move higher in anticipation of the ongoing China NPC meeting.Looking ahead, US Employment Trends, Durable Goods, Australian PMIs (Final), Comments from ECB's Elderson, Holzmann, Supply from the US. Earnings from Fidelity National Information Services, NXP Semiconductors, Vertex Pharmaceuticals, Diamondback Energy, Palantir Technologies, Marriott International & Fox.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

WBZ NewsRadio's Chaiel Schaffel reports. 

In this episode, we hear the story of Vertex Pharmaceuticals, and it's a great one. Because their story is a people story. They've undergone tremendous transformation you might call Digital Transformation, but "digital" is a means to an end. At Vertex, transformation serves to amplify their tremendous culture and create talent velocity throughout the organization. Tune in to hear Kimberly Rose, Executive Director of People Experience, Analytics, and Digital Innovation in Human Resources ---- if a title doesn't illustrate the literal evolution of HR, we don't know what does. Kim shares how onboarding, career navigation, and managing people are all grounded in LISTENING TO PEOPLE at Vertex, and she reminds us one size does not fit all when it comes to employee experience.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. This week's commercialization news includes Dupixent's success in a chronic hives study, Lilly's development of a weekly insulin shot, and BioMarin's plans for growth. The House backs a bill restricting China's role in US biotech, while Lykos CEO is set to depart after FDA rejection and layoffs. The newsletter also discusses key developments in cell therapy and offers insights on utilizing a direct-to-patient model in the healthcare industry. Various resources and upcoming events in the biopharma industry are also highlighted. Biopharma Dive provides in-depth journalism and insights into the latest news and trends shaping the biotech and pharma industries.BridgeBio has reduced its gene therapy budget after data from a trial on an adrenal gland medicine did not meet the company's investment threshold. GlaxoSmithKline has discontinued a herpes vaccine after it did not meet efficacy goals in a phase 2 study. Roivant has launched a new 'vant' focused on a hypertension drug. Centessa's sleepiness drug has shown promising results in early studies, leading to a rise in the company's shares. Additionally, Dupixent has succeeded in a chronic hives study, giving Sanofi and Regeneron a chance to resubmit their application for approval. Investors are also paying attention to Centessa's sleepiness drug. This news comes alongside updates on other pharmaceutical developments, such as Saxenda's effectiveness for children as young as 6 and Roche's expansion of R&D labs. Additionally, the newsletter covers upcoming events and resources for biopharma professionals. Biopharma Dive provides in-depth coverage of news and trends in the biotech and pharma industries, including clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.Iowa has awarded Centene's subsidiary, Iowa Total Care, a Medicaid managed care contract worth $2.8 billion. Telehealth groups are urging Congress and the White House to extend controlled substance virtual prescribing before pandemic-era flexibilities expire. The Biden administration has finalized a rule raising mental health coverage standards for private plans. Steward Health Care received court approval to sell its three most valuable hospitals to Orlando Health for $439 million. The importance of data quality in realizing value from medical imaging data is emphasized by Enlitic. Payers are encouraged to optimize quality and grow revenue through key strategies in an upcoming webinar. Healthcare Dive provides in-depth journalism and insight into the most impactful news and trends shaping healthcare across various sectors like health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.Novo Nordisk showcased its investigational GLP-1 pill that resulted in a remarkable 13% weight loss. This comes after positive Phase I results for the pill, which analysts compared to weight loss pills being developed by Lilly and Pfizer. Expanded coverage for cardiovascular disease under Medicare could have significant implications for Novo's obesity drug, Wegovy. Analysts estimate that the expansion of Wegovy's label beyond obesity could lead to an annual Medicare spending of $145 billion. Meanwhile, GSK has abandoned the development of its herpes vaccine after disappointing Phase I/II results, and Crispr Therapeutics and Vertex Pharmaceuticals are facing challenges in making their sickle cell gene therapy profitable. Novo's other drug, Saxenda, was found to effectively and safely lower BMI in children, according to a study published in NEJM. Additionally, Lilly continues to make progress with its once-weekly insulin, while Bain has raised $3 billion for a fund supporting life sciences companies. The biopharmaceutical industry continues to see changes, with Biomarin facing challenges and Terns moving forward in the obesity spac

Get ready for an insightful conversation as host Rahul Chaturvedi connects with John Alam, CEO of CervoMed, to uncover the revolutionary advancements transforming dementia treatment, with a spotlight on Dementia with Lewy Bodies (DLB). John shares his remarkable journey from practicing medicine to leading cutting-edge biotech innovations, shedding light on the bold breakthroughs in neurodegenerative research and the intense, high-stakes world of clinical trials. This episode reveals how CervoMed is not just advancing dementia care but redefining it, proving that resilience and bold thinking are the keys to success in biotech. Biography: John Alam serves as the Chief Executive Officer at CervoMed, co-founding the company (formerly known as EIP Pharma) in 2014. John is an industry leader in translational medicine with over 30 years of experience creating value to help build companies through clinical development success. Until May 2014, he was therapeutic area head for diseases of aging at Sanofi, where he led all discovery and development activities directed at Alzheimer's disease, as well as a number of other age-related diseases including sarcopenia/frailty, osteoarthritis, chronic pain and many others. From 1997 to 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and Executive Vice President, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. Prior to Vertex, Alam led clinical development of Avonex (interferon beta-1a) for multiple sclerosis at Biogen from 1991 to 1997. John is a member of the board of directors of the Alliance for Aging Research (AAR), a Washington, D.C. based non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. He received a MD from Northwestern University School of Medicine and a BS in Chemical Engineering from the Massachusetts Institute of Technology. In addition, he completed an internal medicine residency at Brigham and Women's Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.

2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. 

Join host Emily Walsh Martin, PhD, and David Altshuler, MD, PhD, Chief Scientific Officer of Vertex Pharmaceuticals. David came to Vertex after a lengthy career in medicine and academic research. David and Emily discuss how David and the team at Vertex think about innovation in drug development and how that impacts how they select programs and approaches for the diseases they focus on. They also cover what he'd love to see happen with new cell and gene platform technologies being brought forward. Now is the time to register for the ASGCT Policy Summit, held in Washington DC on September 23-24. Whether you attend in person or virtually, you will not want to miss this year's program. Great sessions are planned on reimbursement, Medicaid, venture capital, strategic investment outlooks, and the evolution of the regulatory landscape. Advanced registration ends August 23, so register today! ASGCT.org/PolicySummit Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

In this week's episode, Mary Winkels, Global Director, Medical Affairs Training and Capability at Vertex Pharmaceuticals discusses the MSL secret weapon for insightful engagement. Learn more about…

The 10-year Treasury yield rallied a bit after the minutes from the May 1 Fed meeting were released. Just after the close, the yield was trading around 4.43%, up 2 basis points. Oil and gas stocks lagged badly, along with metals and mining stocks. Loar Holdings followed through after clearing an IPO base Tuesday; Monday.com is holding gains well after gapping up on earnings; Vertex Pharmaceuticals is near the top of a shallow cup base.

Grace E. Niwa is a former piano prodigy who received a Master's Degree in Piano Performance from Juilliard, made her Carnegie Hall debut - and then decided to not pursue a professional career in music. Grace's subsequent professional life of multiple pivots includes being the Principal of her own PR firm and serving as Principal in a Global Executive Search firm. These days, Grace is the VP of Global Talent Acquisition, Talent Management and Early Career at the red-hot Vertex Pharmaceuticals, a global pharma powerhouse. Grace arrived at Vertex after serving as VP of Talent Acquisition and Executive at the equally celebrated Flagship Pioneering. Grace is a disruptor and visionary in the highly competitive world of Global Talent Acquisition, with a drive and discipline that are animated by her early training as a concert pianist.

Vertex Pharmaceuticals' acquisition of Alpine Immune Sciences will bolster a growing kidney disease franchise that could help diversify Vertex's business beyond its blockbuster cystic fibrosis franchise. On the latest BioCentury This Week podcast, BioCentury's editors discuss what attracted Vertex to Alpine and why it believes its newly acquired therapy can outshine others for IgA nephropathy. The editors discuss how Goldman Sachs aims to scale private biotechs via its venture strategy and the likely key factors for CMS as it determines prices for the first cohort of drugs in Medicare drug price negotiations under the Inflation Reduction Act. They also preview BioCentury's first R&D conference — Grand Rounds — which will focus on the biotech industry's interface with academia, bringing together decision-makers and the next innovators in Nashville, Sept. 9-11. This week's podcast is sponsored by Jeito Capital. 

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Nando Sommerfeldt und Philipp Vetter über Inflations-Frust, ein episches Nvidia-Kursziel und ein Lob für Alibaba. Außerdem geht es um TSMC, Infineon, Nike, Lululemon, Under Armour, Adidas, Vertex Pharmaceuticals, Alpine Immune Sciences, Volkswagen, BMW, Mercedes-Benz, Stellantis, Mingyang, Goldwind, Siemens Energy, Oersted, Vestas, Rio Tinto, Glencore, Anglo American, Teck Resources, Newmont, Barrick Gold Agnico Gold Eagles, Hudbay Minerals, Pan American Silver, Albemarle, MP Materials, South32, Earth Gold Fund UI (A0Q2SD), Earth Exploration Fund UI (A0J3UF), VanEck Global Mining ETF (A2JDEJ). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

On this episode, we speak with Katie Weissman from Vertex Pharmaceuticals to learn about their company culture, investment in early-career talent and much more.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Several developments in the biopharma industry were reported on March 6. Gilead made a bet on 'trispecifics' in a new cancer drug deal, Alumis secured $259 million for its work on a drug targeting Tyk2, Regenxbio's data showed promise in Duchenne gene therapy, Alnylam and Roche's blood pressure drug performed well in a mid-stage trial, and Sionna raised $182 million to challenge Vertex in cystic fibrosis treatment. The sector saw a surge in biotech IPOs at the beginning of 2024, prompting discussions on whether this trend will continue. The biosimilars market in the US has been growing steadily since its slow start in 2015. Additionally, Brazil declared a state of emergency due to dengue cases, AstraZeneca invested in the UK for pandemic preparedness, and companies rushed to preserve skeletal muscle after the success of obesity drugs.Dexcom has received FDA approval for the first over-the-counter continuous glucose monitor for people with type 2 diabetes. Vicarious continues to focus on launching its soft tissue robot despite financial struggles. Smiths Medical has recalled nearly 86,000 syringe pumps due to a software issue. Haemonetics is set to acquire Attune Medical for $160 million. Medtronic estimates up to 40 job losses in Ireland as part of restructuring efforts. The EU Medical Device Regulation is causing challenges for small and medium-sized medtech companies. Other news includes Philips being sued for milestone payments, a dentistry AI developer receiving a $53 million investment, and CMS rolling out provider flexibilities amid cyberattack fallout.Alumis has raised $259 million in a Series C funding round, making it the largest haul in 2024 for a private biotech company. The California-based biotech plans to use the funding to move its tyk2 inhibitor into phase III for plaque psoriasis, potentially challenging competitors Bristol Myers Squibb and Takeda in the autoimmune market. Other key focuses for investors in 2024 include psychedelics and solid tumors. Sandoz has received FDA approvals for the first two biosimilars for Amgen's denosumab, while Sionna Therapeutics has closed a $182 million Series C round to potentially challenge Vertex Pharmaceuticals in the cystic fibrosis market. Overall, experts anticipate increased interest in the autoimmune and obesity spaces this year, following a trend of heightened investment in oncology and neuroscience in 2023.In 2024, investors are expected to focus on psychedelics, solid tumors, autoimmune, and obesity drugs in the biopharma industry. Pfizer's decision to prioritize biologics over small molecules was influenced by the Inflation Reduction Act (IRA). Researchers suggest that the IRA could potentially discourage drug developers from pursuing subsequent indications for existing drugs, leading to a decrease in new drug approvals. Biopharma mergers and acquisitions are on the rise, with Biospace launching an M&A tracker to keep track of industry transactions. The 10th Annual American Biomanufacturing Summit is set to bring together industry leaders to discuss current trends and best practices. In other news, AstraZeneca lost a court case related to the IRA, the ADC market in oncology is expected to reach $30 billion by 2028, and various biopharma companies have secured substantial funding for drug development. Pfizer is focusing on four main cancer types and aims to launch eight blockbuster drugs by 2030.

2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. In our first news, Walgreens has appointed Mary Langowski as the new president of its U.S. healthcare segment, replacing John Driscoll. Molina Healthcare has reported a loss of 500,000 members due to redeterminations, but expects proposed 2025 rates to boost its benchmark rate. UnitedHealth's COO, Dirk McMahon, is retiring after two decades at the company. The American Hospital Association (AHA) has called for more payer oversight in resolving disputes over surprise medical bills.Moving on to the next news, Amgen, Roche, and Pfizer are looking to enter the GLP-1 weight loss market, challenging Novo Nordisk and Eli Lilly. These companies are developing their own versions of diabetes and weight loss drugs. Smaller biotech companies have also shown promising results in clinical trials with their own GLP-1 agonists. Amgen, Roche, and Pfizer are currently in the clinical stages of developing their GLP-1 receptor agonists and could soon enter the weight loss and obesity markets.In financial news, Eli Lilly has reported revenue of over $9.3 billion in Q4 2023, surpassing expectations. The company credits the strong performance to the demand for their weight-loss drug Zepbound and the diabetes treatment Mounjaro. Vertex Pharmaceuticals announced positive results for its cystic fibrosis triple combination therapy in two randomized controlled trials. GlaxoSmithKline's Blenrep combination therapy also achieved a phase III win in multiple myeloma. Novartis has acquired German biotech company MorphoSys to strengthen its oncology portfolio. Bristol Myers Squibb highlighted their comprehensive approach to cancer research.Shifting gears to regulatory news, the FDA panel has recommended new standards for pulse oximeters due to concerns of bias. Cardinal Health has expanded its recall of Monoject syringes due to compatibility problems. The FDA is planning to reclassify most high-risk in vitro diagnostic devices (IVDs) to ease the path for clearance. Edwards has received FDA approval for the first transcatheter tricuspid valve replacement treatment. ECRI has identified usability challenges for at-home devices and inadequate device cleaning instructions as top health technology hazards.Finally, several biopharmaceutical companies are focusing on neuroinflammation as a potential target for treating Alzheimer's disease. Vertex Pharmaceuticals' non-opioid pain drug, VX-548, recently failed in a Phase III trial. Bristol Myers Squibb takes a comprehensive approach to cancer research. Takeda's immunoglobulin therapy for Clostridium difficile infection (CDI) has been approved by the FDA. Novartis has dropped a blood cancer asset after disappointing Phase III results. Merck's Keytruda has achieved Phase III wins in kidney and bladder cancer. BMS's Opdivo has failed in a late-stage kidney cancer trial.These developments indicate positive progress in the pharmaceutical industry, particularly in the areas of cancer treatment and rare diseases like cystic fibrosis. Companies continue to innovate and strive for breakthrough therapies that can improve patient outcomes.Thank you for listening to Pharma and Biotech Daily. Stay tuned for more updates in the world of Pharma and Biotech.

Last month the FDA approved a new treatment for sickle cell disease, the first medical therapy to use CRISPR gene editing technology. It works by identifying the gene or genes causing the disorder, modifying those genes and then returning them to the patient's body.There are now two gene therapies offered by pharmaceutical companies for sickle cell disease: Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia from BlueBird Bio. But prices for these one-time treatments are steep: Casgevy costs $2.2 million per patient and Lyfgenia $3.1 million.Both promise a full cure, which would be life-changing for patients with this debilitating condition. Over 100,000 Americans, mostly of African descent, have sickle cell disease.This milestone raises more questions: What will be the next disease that CRISPR can help cure? And is it possible to reduce the costs of gene therapy treatments?Ira talks with Dr. Fyodor Urnov, professor of molecular and cell biology and scientific director of technology and translation at the Innovative Genomics Institute, based at the University of California, Berkeley, about the future of CRISPR-based cures.Transcripts for this segment will be available the week after the show airs on sciencefriday.com. To stay updated on all things science, sign up for Science Friday's newsletters.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. AstraZeneca, the pharmaceutical company, recently had its day in court regarding a potential injunction on the Medicare drug pricing law. The outcome of the hearing will have significant implications for the healthcare industry. Meanwhile, Vertex Pharmaceuticals' non-opioid pain drug failed to outperform Vicodin in clinical trials, but experts believe that more can be done to develop effective non-opioid pain medications. In other news, a study has found that the Inflation Reduction Act's drug price negotiation program will have only a modest impact on global biopharma revenues and is unlikely to result in significant cuts to research and development. Sanofi reported a $600 million net loss in Q4 2023 due to various factors, despite strong sales of its blockbuster drug Dupixent. Additionally, Roche's 2024 strategy aims to combat low growth through pipeline cuts and mergers and acquisitions. Daiichi Sankyo has raised its sales forecast for Enhertu due to non-US growth, and the FDA Commissioner has highlighted adcomm reform, funding, and AI as priorities for the agency.Moving on to other industries, Pepsi is generating excitement for the Super Bowl with its "Get Wild" campaign for Pepsi Wild Cherry. Gatorade, another brand under PepsiCo, is launching a free membership platform to fuel its digital transformation. Jif, the peanut butter brand, is tackling "celery neglect" on game day by offering free peanut butter through a tie-up with Gopuff. In social media news, CEOs faced tough questions about child protection in a Senate session, with senators arguing that social platforms need to do more to protect young users. Advertiser Perceptions' Erin Firneno advises media companies on how to communicate brand momentum in 2024. The Super Bowl LVIII ads are being tracked, with reveals from Michelob Ultra and Paramount+, and teasers from Uber and Nyx. Google, CrowdStrike, and State Farm will also be returning with ads. Lastly, Marketing Dive's daily newsletter offers insights and news for marketing leaders.In the field of research, BioIVT is a leading provider of control matrices, offering biofluids, tissues, and matrices from commercial animals for research purposes. These biospecimens undergo strict quality control measures to enhance assay sensitivity. BioIVT offers a wide range of control matrices, including serum, cerebrospinal fluid (CSF), ocular fluid, and various tissues. These samples can be shipped fresh, cold, or frozen to ensure reliability and quality. Additionally, BioIVT provides matrices from commercial animals.Thank you for listening to Pharma and Biotech daily. Stay tuned for more important updates in the world of Pharma and Biotech.

For the free course "ChatGPT4 for Medical Writers and Editors," go to learnAMAstyle.com Visit Nascentmc.com/podcast for detailed show notes and links.         Erdafitinib for Urothelial Carcinoma: The FDA has fully approved erdafitinib (Balversa) for advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations in adults. This follows its initial accelerated approval and is based on the phase 3 THOR trial results, showing improved survival rates and manageable side effects. Erdafitinib reduced death risk by 36% and had a lower treatment discontinuation rate compared to chemotherapy.        TTFields in NSCLC: The FDA is reviewing a premarket approval application for tumor treating fields (TTFields) combined with standard therapies for platinum-resistant non–small cell lung cancer. TTFields, first approved in 2011, disrupt cancer cell division and showed enhanced survival in NSCLC patients when combined with immune checkpoint inhibitors or docetaxel, without increasing systemic toxicities. The FDA's decision is expected in the second half of 2024.        AI-Powered Device to Detect Skin Cancer: The FDA has approved the first AI-powered handheld device by DermaSensor for assisting in skin cancer detection. It uses AI-driven spectroscopy for analyzing skin lesions and is based on a study involving over 1000 patients. While not a primary screening tool, it aids in detecting melanoma and other skin cancers, especially in patients over 40, and requires further validation testing.        Casgevy for Transfusion-Dependent Beta Thalassemia: The FDA has approved Casgevy (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for treating transfusion-dependent beta-thalassemia. This follows its approval for sickle cell disease and marks the first CRISPR gene-editing technology application for this condition. The approval came ahead of the anticipated date and follows Bluebird Bio's 2022 approval for a similar gene therapy.        HyQvia for CIDP: HyQvia, an immune globulin infusion 10%, has been approved by the FDA for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. Initially approved for primary immunodeficiency, HyQvia is the only product combining immunoglobulin with hyaluronidase, allowing for monthly subcutaneous infusions. The approval is based on its demonstrated efficacy in preventing neuromuscular disability relapse.        Physicians' Understanding of FDA Approval Process: A national survey reveals that many physicians have limited understanding of the FDA's drug and medical device approval processes. Only 41% of the surveyed physicians reported moderate or better comprehension of the drug approval process. Despite believing in the adequacy of FDA standards, there's a call for more rigorous post-marketing studies and enhanced education on FDA processes to avoid misconceptions and inaccurate patient advice.

Listen to Len Bacharier, MD and Sharon Dell, MD, FRCPC, as they highlight the natural course of pediatric asthma progression over time, discuss differences between spontaneous remission and on-treatment clinical remission, and provide a commentary on what we have learned from the recent developments around remission in adults and how it could relate more specifically to pediatric populations.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Len Bacharier, MD has served as an advisor, consultant, speaker, and/or investigator for AstraZeneca, Avillion, DBV Technologies, Genentech/Novartis, GlaxoSmithKline, Kinaset, OM Pharma, Recludix, Regeneron Pharmaceuticals, Inc., Sanofi, Vertex; has provided grant and/or research support for NIH (NHLBI, NIAID), Regeneron Pharmaceuticals, Inc., Sanofi; and has provided other support for DBV Technologies Sharon Dell, MD has served as an advisor, consultant, and/or speaker for  AstraZeneca, Novartis, Regeneron Pharmaceuticals, Sanofi; and has provided grant and/or research support for Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, Vertex Pharmaceuticals © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2305935 v1.0 12/2023 MAT-US-2305475 v1.0 - P Expiration Date: 12/22/2025

Frank Holland and the investment committee debate the road ahead for your money. The panel reacts to the recent tear in transportation stocks. The call of the day is on Vertex Pharmaceuticals. The chart of the day is on lithium. Investment Committee Disclosures

Dow rises more than 500 points to a new record high. Plus: Apple shares climb 1.7% to their highest level ever. Vertex Pharmaceuticals shares finish 13.2% higher after it reported promising study results for one of its experimental pain medicines. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

In the dynamic field of life sciences, skillful operators ensure the efficient development of medical innovations, while insightful investors provide crucial capital and strategic guidance. Rich Aldrich's 30+ year career uniquely bridges both sides, having played key roles in founding and managing successful ventures in the industry.Rich Aldrich is a co-founder and partner at Longwood Fund. Before Longwood, he founded RA Capital Management and has been instrumental in co-founding and contributing to the growth of notable biotech companies, including Sirtris Pharmaceuticals, Concert Pharmaceuticals, and Vertex Pharmaceuticals, among others.In this episode, Hercules Capital's Janice Bourque and Rich Aldrich discuss key lessons in operations and investment, the advantages of public investing, the attributes of a strong management team, Rich's reflections on the industry and much more.Topics include:Transitioning from operations to investingRich's key lessons from public investmentsThe advantages of public investingAttributes of a strong management teamCurrent areas of scientific interest for RichEmerging challenges in life sciencesDeciding whether or not to commercializeRich's reflections on the industry's evolutionAnd other topics…Rich Aldrich is a co-founder and partner of Longwood Fund, an early-stage life science venture firm. With over 30 years of experience in the life sciences space, he has co-founded and helped build several biotech companies including Sirtris Pharmaceuticals, Concert Pharmaceuticals, and Vertex Pharmaceuticals, among others. Before the Longwood Fund, Rich founded RA Capital Management, a life sciences investment fund with an AUM of over $9 billion.Rich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth. He currently serves as a Director of Longwood portfolio companies Axial, Sitryx Therapeutics, and Colorescience.

Synopsis: Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Keith and Jeremy discuss the arc of their careers and how they go to where they are today. They talk about the differences working in big pharma vs. a smaller biotech like Prime. They discuss the importance of companies investing in safety and what they've learned in terms of indication selection frameworks within the context of gene editing. Finally, they talk about their goal of engaging in partnerships down the road, and the importance of having transparency within their organization. Biography: Keith Gottesdiener, MD is President and Chief Executive Officer of Prime Medicine and has served as a member of our Board of Directors since July 2020. From October 2011 until March 2020, Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company that develops therapeutics in rare genetic obesity. During that time, Rhythm submitted a New Drug Application for setmelanotide in two indications, for which setmelanotide was subsequently approved. Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at the Dana Farber Cancer Institute. He then joined the faculty as an assistant professor at Columbia University, where he started an independent research laboratory with NIH RO-1 funding, ending his academic career as Associate Clinical Professor of Medicine at the time he left to join Merck in 1995. Jeremy Duffield, MD, PhD, FRCP, is the Chief Scientific Officer of Prime Medicine. He has many years of drug discovery experience at Vertex Pharmaceuticals and Biogen Inc. preceded by a distinguished career in academic medicine. Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies. At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases. Dr. Duffield received his B.A. and M.D. (B.M., B.Ch.) from Oxford University and a Ph.D. in Immunology from the University of Edinburgh in the laboratory of Sir John Savill.

The world's first approval of a CRISPR-based gene editing therapy, granted by the U.K.'s MHRA, was a milestone for the technology that was just discovered about 12 years ago. On the latest BioCentury This Week podcast, BioCentury's editors discuss the implications of the landmark and the challenges that still face partners Vertex Pharmaceuticals and CRISPR Therapeutics in launching and scaling the rollout of Casgevy exagamglogene autotemcel (exa-cel) in the U.K. and beyond. The editors also discuss the unintended consequences of the Inflation Reduction Act (IRA) on the development of orphan drugs and new legislation that aims to address the problem by providing an exemption to price negotiations for therapies that are approved only for orphan indications, regardless of how many. The team also reflects on the legacy of FDA's Janet Woodcock ahead of her planned retirement next year; the sentiment coming out of last week's Jefferies Healthcare Conference in London; and the aftermarket performance of two market debuts last week from antibody-drug conjugate CMO WuXi XDC Cayman and Mural Oncology.Music for the 24th Bio€quity Europe promo produced by:Thomas de Paula Eby, Andreas Unge, Epidemic Sound via Getty Images

Scott Wapner and the investment committee discuss the tech run as the Nasdaq goes for its longest winning streak in two years. The experts detail their latest portfolio moves. The calls of the day are on Nike, Home Depot and Lowe's. Earnings movers include Uber, Vertex Pharmaceuticals and NXP Semi. The desk debates the energy trade with oil prices at two-month lows.Investment Committee Disclosures

  A former Samsung executive allegedly stole plans in order to build a chip plant down the road from the existing factory. What could possibly go wrong? (00:15) Bill Mann and Deidre Woollard discuss: - The high value of getting a leg up on the competition in the semiconductor industry. - If companies can do anything to keep secrets from leaking out. - Why Alphabet's adtech is attracting regulators' attention. (13:53) Ricky Mulvey and Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. Companies discussed: GOOG, GOOGL,KO, VRTX, SSNLFHost: Deidre Woollard Guests: Bill Mann, Ricky Mulvey, Kirsten Guerra Producer: Ricky Mulvey Engineer: Tim Sparks